Introduction
Breast cancer, a life-threatening deadly disease, contains biological entities associated with specific morphological and histological features, clinical behaviors and complex genetic/epigenetic alterations and gene product defects (1) . Despite recent progress in breast cancer diagnosis and treatment, the survival rates for patients with late-stage/ metastatic breast cancer remain poor. Thus, identification and determination of new genes/pathways involved in breast cancer carcinogenesis, especially metastasis, will help to develop safer and faster diagnosis and better disease outcome predication following treatment of this dangerous disease.
Microtubule (MT)-associated kinesin superfamily motor proteins (Kifs) orchestrate function and dynamics of MTs, the unique and highly dynamic 25 nm diameter cylindrical tubulin polymers composing interphase cytoskeleton and mitotic spindle that are essential for many cellular processes including intracellular organelle/macromolecule transportations, cell shape, cytoskeleton dynamics, cell migration and cell division (2, 3) . Kinesins share significant sequence homology in their conserved motor domains and utilize adenosine triphosphate hydrolysis in a MT-dependent manner to fuel their movement along MTs and/or regulate MT dynamics (4) . Kinesins transport specific cargoes along the surface lattice of MTs, cross-link/slide MTs to adjacent MTs or other cellular structures and/or modulate MT assembly/disassembly by coupling MT growth/shrinkage (polymerization/deploymerization). Because of their critical cellular functions, several kinesins have been implicated in carcinogenesis (5) (6) (7) (8) (9) . For example, gene amplification and/or overexpression of Kif14, a member of kinesin-14 family, and mitotic centromere-associated kinesin, a member of kinesin-13 family, have been reported in several human cancers, whereas inactivation of Kif4A, a member of kinesin-4 family, by gene knockout in mouse embryonic stem cells results in abnormal cell division, checkpoint activation and tumor formation (7) (8) (9) (10) .
Kif18A, a member of kinesin-8 family, has been shown to play pivotal roles in regulating MT dynamics and cell division in eukaryotes (11) (12) (13) (14) (15) (16) (17) (18) (19) . Previously, we and others demonstrated that members of kinesin-8 in yeast, Drosophila and mammalian cells are essential for MT dynamics, chromosome congression and cell division (17, (19) (20) (21) (22) (23) (24) . Kif18A localizes to MT array plus-ends in interphase and spindle MT plus-ends, especially kinetochore MT (K-fiber) plus-ends, during mitosis [(17) and see Figure 3A ]. Ablation of Kif18A function in mammalian cells resulted in aberrant long mitotic spindles, abnormal chromosome congression, delays of the prometaphase to metaphase transition and activation of the mitosis arrest deficient 2-dependent spindle assembly checkpoint (17, 19) . Biochemical analysis and single molecule microscopy revealed that kinesin-8 motors function as dual motile MT depolymerases that move along MTs toward the plus-ends and depolymerize MTs at the plus-ends (25, 26) . Indeed, accumulation of Kif18A on kinetochores coordinates with the length and stability of kinetochore K-fibers thereby controlling chromosome movements (15) . Similar effects of Kif18A on regulation of interphase MT dynamics might also affect MT array/ cytoskeleton dynamics and cell migration (27) .
Given the fact that Kif18A plays critical roles in modulating MT dynamics and mitosis, perturbation of Kif18A function might cause cell transformation and oncogenesis. In this study, we investigate Kif18A involved in human breast carcinogenesis. We find that there is a significant association between Kif18A expression and tumor grade, metastasis and survival in breast cancer. Functional analyses show that overexpression of Kif18A in human breast cancer cells causes multinucleation, whereas suppression of Kif18A results in inhibition of cancer cell growth both in vitro and in vivo. In addition to the effects in mitosis, ablation of Kif18A function also perturbs cell migration and induces cell anoikis. Thus, these results indicate that Kif18A is involved in proliferation, migration and anoikis in human breast cancer cells and may be a potential target for cancer therapy.
Materials and methods
Complementary DNA microarray analysis The ONCOMINE database and gene microarray analysis tool, a repository for published complementary DNA microarray data (http://www.oncomine.org) (28) were explored. Based on the data, we assessed messenger RNA (mRNA) expression of Kif18A in normal breast tissues and breast cancers. Furthermore, we examined the correlation of Kif18A expression with clinicopathologic parameters such as tumor grade, metastasis and patient survival. All data were log transformed, median centered per array, and the standard deviation was normalized to one per array as described (28) .
Cell lines and tissue samples
Four human breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-453 and MDA-MB-435S) and a human cervical carcinoma cell line (HeLa) were routinely maintained in Dulbecco's Modified Eagle's medium supplemented with 10% (vol/vol) fetal bovine serum at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .
Primary breast cancer specimens and adjacent histologic normal tissues were obtained from 15 patients who underwent surgery in Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. All specimens were immediately frozen in liquid nitrogen and stored at À80°C until use. The patients' medical data and lifestyle for cancer risk factors (e.g. smoking and family history of cancer) were documented with informed consent.
Plasmids, siRNAs and antibodies
The full-length coding region of Kif18A complementary DNA was polymerase chain reaction-amplified and then cloned into EcoRI and SalI sites of the mammalian expression vector pEGFP-C1. Small interfering RNA (siRNA) expressing vectors were constructed by introducing synthetic double-stranded oligonucleotides (Kif18A 5#-ACAGATTCGTGATCTCTTATTCAAGAGAT-AAGAGATCACGAATCTGT-3# or non-silencing: 5#-TTCTCCGAACGTGT-CACGTTTCAAGAGAACGTGACACGTTCGGAGAA-3#) into the pGCsi-U6/Neo/GFP vector (Genechem, Shanghai, China). All constructs were fully sequenced. esiRNA (a pool of endonuclease-RNaseIII prepared siRNAs) targeting the 3# untranslated region ($400 bp) of human Kif18A gene or control Luciferase gene was made as described previously (19) .
Rabbit polyclonal anti-Kif18A antibodies (a-Kif18A) were generated and affinity-purified using bacterially expressed purified His-tagged Kif18A-C-terminus fusion protein (amino acids 601-898) as described previously (19) . Rabbit polyclonal anti-PRC1 antibodies (a-PRC1) were described previously (19) . Mouse anti-b-actin antibody and mouse anti-a-tubulin antibody were purchased from Sigma-Aldrich (St Louis, MO). Anti-Akt, anti-phospho-Akt (pAkt; Ser473), anti-extracellular signal-regulated kinase (Erk), anti-phospho-Erk (Tyr204) and anti-epidermal growth factor receptor antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-EB1 antibody was purchased from BD Transduction Laboratories (San Diego, CA). All secondary antibodies were purchased from Jackson Immunoresearch (West Grove, PA).
Transfection, generation of stable cell lines and MTT assay For transient transfection, 4 Â 10 4 cells per well in six-well plates were cultured overnight and then transfected with mammalian expression plasmids (pEGFP-Kif18A, pGCsi-U6/Neo/GFP-Kif18A, etc.) or esiRNA (Kif18A or Luciferase) using Lipofectamine 2000 reagent (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer's instruction. Three days after transfection, cells were collected or fixed, followed by immunoblotting or immunofluorescence analysis. For generation of stable cell lines expressing green fluorescent protein (GFP)-Kif18A or Kif18A small hairpin RNA, cells were transfected with the corresponding plasmids. Two days after transfection, cells were trypsinized, transferred to 10 cm cell culture dishes and selected by complete medium plus 1 mg/ml of G418 for $2 weeks. G418 resistant colonies that stably overexpressed GFP-Kif18A or downexpressed Kif18A were picked up and identified by immunoblotting analysis. Thiazolyl Blue Tetrazolium Bromide (MTT) assays were performed as described (9) . In brief, 1 Â 10 3 cells in 100 ll culture medium were plated into a well of 96-well plates. After culturing cells for an appropriate time, 10 ll of 5 mg/ml MTT was added into each well and continued to culture for 4 h. Then, the cell culture medium was replaced by 100 ll of dimethyl sulfoxide. Thirty minutes after dimethyl sulfoxide addition, the plates were placed on a microplate autoreader (Bio-Rad, Hercules, CA). Optical density was read at 570 nm wavelength and cell growth curves were determined according to the optical density value.
Immnunoblotting and immunofluorescence analyses
Immunoblotting analysis was performed as described previously (19) . In brief, cells were lysed in 1% NP-40 lysis buffer (19) and cleared by centrifugation. Cell lysates containing equal amount of proteins were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) and immunoblotted with a-Kif18A (1:500 dilution), a-PRC1, anti-Akt, anti-phospho-Akt (pAkt; Ser473), anti-Erk, anti-phospho-Erk (Tyr204), anti-epidermal growth factor receptor, anti-b-actin and anti-a-tubulin antibodies (all at 1:1000 dilution). After incubation with secondary antibody, protein signals were visualized by enhanced chemiluminescence.
For immunofluorescence analysis, cells grown on glass coverslips were fixed with cold methanol:acetone (1:1) for 5 min and then blocked with 10% goat serum in phosphate-buffered saline contained 0.1% Triton X-100. Twenty minutes later, cells were incubated with primary antibodies (a-Kif18A, 1:100 dilution; anti-EB1 antibody, 1:500 dilution or anti-a-tubulin antibody, 1:5000 dilution) for 2 h at room temperature followed by another 2 h incubation with appropriate secondary antibodies (1:500 dilution). Cells were then stained with 1 lg/ml of 4#,6-diamidino-2-phenylindole in phosphate-buffered saline for 5 min and coverslips were mounted on a clean slide with 5 ll of FluoroGuard antifade reagent (Bio-Rad). The cell images were obtained on an inverted Leica DMIRE2 microscope equipped with a CCD camera and processed by using Simple PCI software (Compix, Sewickley, PA).
Time-lapse microscopy Time-lapse microscopy was performed as described previously (19) . In brief, HeLa cells stably expressed yellow fluorescent protein-tubulin or EB1-GFP fusion proteins were grown on a 35 mm poly-lysine coated glass bottom microwell dish (MatTek, Ashland, MA) for 24 h and then transfected with Luciferase or Kif18A esiRNAs using Lipofectamine 2000 reagent. One day after transfection, cells were changed into CO 2 -independent medium (Gibco-Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum overnight. The dish was then covered with mineral oil (Sigma-Aldrich) and transferred to a heated stage (37°C) under a Â63 oil objective on an inverted Leica DMIRE2 microscope. Fluorescence images of live cells were collected at 3 s intervals for 15 min. Movie images were collected and processed by using Simple PCI (Compix) software and exported as QUICKTIME (Apple Computer, Cupertino, CA) movies.
Soft agar colony formation, cell migration and anoikis assays Soft agar colony formation assays were performed as described (10) . In brief, 2 Â 10 3 cells suspended in complete medium containing 0.33% agar were plated in a hard agar (0.6% agar in complete medium) coated well in six-well plates. Three weeks after plating, cells were stained by 0.02% iodonitrotetrazolium chloride (Sigma-Aldrich) to visualize colonies. After photography, colonies were counted using Image-Pro Plus 6.0 software (Media Cybernatics, Bethesda, MD). Cell migration assays were performed using 8 lm pore polycarbonate membrane Transwell chambers (Costar, Cambridge, MA). In brief, 1 Â 10 5 cells were cultured in the upper chamber with serum-free medium. The lower chamber contained complete medium (10% fetal bovine serum). After incubation at 37°C, 5% CO 2 for 12-24 h, cells adherent to top surface of the membrane were removed with a cotton applicator, whereas cells migrated to bottom surface were fixed with 70% methanol and stained with crystal violet. The migrated cells on the bottom surface of the membrane were photographed and counted on an inverted microscope. Anoikis assays were performed as described (29) . In brief, cells suspended in complete medium were seeded in polyhydroxyethylmethacrylate (Sigma-Aldrich)-coated 35 mm wells and cultured in a humidified (37°C, 5% CO 2 ) incubator for 18 h. After incubation, cells were harvested, stained with Annexin V-FITC apoptosis detection kit (Biosea, Beijing, China) and then analyzed by flow cytometry.
Xenograft assays in nude mice
Cells stably expressing pGCsi-U6/Neo/GFP-non silencing (designated as control RNAi), cells stably expressing pGCsi-U6/Neo/GFP-Kif18A (designated as Kif18A RNAi) or parental cells (1 Â 10 6 ) together with 100 lg of Matrigel (Becton Dickinson, Bedford, MA) were inoculated into mammary fat pads of athymic nude (nu/nu) mice (Vital River Laboratories, Beijing, China; body weight, 15-17 g). Mice were maintained in accordance with institutional animal welfare guidelines concordant with National Institutes of Health species criteria. Tumor growth was recorded twice a week with a caliper-like instrument. Tumor volume was calculated according to the formula volume 5 (width 2 Â length)/2. Seven weeks after inoculation, mice were killed, and the final volume and weight of tumor tissues were determined. Then, tumors were fixed in 4% polyformaldehyde, stained with hematoxylin and eosin and examined under a microscope. Two independent experiments were performed.
Statistical analysis
Results of in vitro and in vivo experiments were depicted as mean ± SD. Student's two-sided t-test was used to compare values of test and control samples. P , 0.05 indicated significant difference.
Results

Kif18A is overexpressed in human breast cancer
To determine if Kif18A has a role in human breast carcinogenesis, we examined expression levels of Kif18A mRNA in public available human breast cancer microarray studies using the ONCOMINE database analysis (for details, see Materials and Methods). Our results revealed that expression levels of Kif18A mRNA were upregulated in breast cancer tissues when compared with normal breast tissues ( Figure 1A , Class 1) (30) . Importantly, we found that overexpression of Kif18A mRNA was associated with pathologic and prognostic parameters of breast cancers. High levels of Kif18A mRNA were correlated with tumor grade ( Figure 1A , Class 2) (available at http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc5 GSE2109) and poor overall survival of patients ( Figure 1A , Class 4) (32). Increased Kif18A mRNA expression also predicted breast cancer recurrence and poor outcome. Patients with distant metastasis had significant high levels of Kif18A mRNA expression when compared with those with no distant metastasis ( Figure 1A , Class 3) (31).
To further investigate if Kif18A protein levels were also upregulated in human breast cancer, we generated rabbit polyclonal antibodies against bacterially expressed His-tagged-Kif18A C-terminal Kif18A is involved in human breast carcinogenesis polypeptide. Immunoprecipitation and immunoblotting analyses showed that anti-Kif18A antibodies (a-Kif18A), but not control preimmune antisera, specifically recognized the 102 kDa of endogenous Kif18A protein in HeLa cell lysates (supplementary Figure 1A is available at Carcinogenesis Online). We examined expression levels of Kif18A protein in 15 matched samples of human primary breast tumors (T) and adjacent histologic normal tissues (N) using immunoblotting analysis with a-Kif18A. As shown in Figure 1B , Kif18A protein levels were upregulated about $2-to 5-fold in 10 of 15 malignant tumor samples. High levels of Kif18A protein expression were also detected in two (MCF-7 and MDA-MB-231) of four (MCF-7, MDA-MB-231, MDA-MB-435S and MDA-MB-453) human breast cancer cell lines examined ( Figure 1C ). Together, these results indicate that Kif18A is overexpressed in most of human breast cancers.
Ectopic overexpression of Kif18A in human breast cancer cells results in multinucleation
To determine the consequences of overexpression of Kif18A in breast cancer cells, we stably overexpressed GFP-tagged Kif18A (GFP-Kif18A) in MCF-7 cells using mammalian expression construct GFPKif18A. Two clones (Kif18A-1 and Kif18A-2), which ectopically expressed GFP-Kif18A at 1-to 2-fold of endogenous Kif18A protein, and one vector control clone (pEGFP-C1) were selected for further analysis (Figure 2A ). Immunofluorescence analysis revealed that population of binucleated/multinucleated cells was significantly higher in cells overexpressing GFP-Kif18A than in control cells (11-13% versus 3.5%) ( Figure 2B and C) . Similar results were also obtained from MDA-MB-231 and MDA-MB-453 cells (data not shown). These results indicate that overexpression of Kif18A in human breast cancer cells resulted in multinucleation, a characteristic of aneuploidy/polyploidy that is associated with tumor development and/or progression.
Suppression of Kif18A expression in breast cancer cells inhibits cell proliferation in vitro and tumor formation in vivo To better understand the biological functions of Kif18A and its role in carcinogenesis, we examined expression and subcellular localization of Kif18A during the cell cycle in detail using affinity-purified a-Kif18A. We used HeLa cells for these studies since HeLa cells were easily synchronized through the cell cycle (19) . HeLa cells were synchronized at G 1 /S by a double thymidine block and then released into different stages of the cell cycle by addition of fresh medium. Cell cycle parameters were determined by fluorescence activated cell sorting analysis (supplementary Figure 1B is available at Carcinogenesis Online). Immunoblotting analysis indicated that, consistent with previous reports (17) , expression levels of Kif18A protein were regulated during the cell cycle showing lower expression in G 1 , then increasing in S and peaking in G 2 /M (supplementary Figure 1C is available at Carcinogenesis Online). Furthermore, we observed mobility shifts of Kif18A protein in G 2 /M, suggesting that Kif18A is also modified by posttranslational modification (i.e. phosphorylation) during these stages of the cell cycle. Consistent with the notion, treatment of taxol-treated mitotic cell lysates with k-phosphatase resulted in collapse of the mobility shifts of Kif18A protein, indicating that the mobility shifts of Kif18A during G 2 /M are due to phosphorylation (supplementary Figure 1D is available at Carcinogenesis Online). Together, these results indicate that not only expression levels but also phosphorylation levels of Kif18A are regulated during the cell cycle.
Immunofluorescence analysis confirmed the immunoblotting results. Levels of Kif18A staining were low in G 1 cells but increased dramatically in S-G 2 /M cells. In interphase cells with stronger Kif18A staining, Kif18A localized in the nuclei and cytoplasm with a punctate staining pattern ( Figure 3A) . The punctate cytoplasmic Kif18A staining was located onto ends of microtubules ( Figure 3A ) and colocalized with EB1 staining at interphase MT array plus-ends ( Figure 3B ). In mitosis, consistent with published results (17), Kif18A was mainly detected on centromere/kinetochore regions (brighter staining) although some Kif18A staining was also observed on spindles and plus-ends of astral MTs in prometaphase and metaphase cells. In anaphase and telophase cells, the majority of Kif18A translocated to the spindle midzone/midbody although staining of Kif18A on spindle and plus-ends of astral MTs could be detected. Similar subcelluar localization results were also obtained in cells ectopically expressing EGFP-Kif18A fusion protein (supplementary Figure 2 is available at Carcinogenesis Online). Together, the unique subcellular localization of Kif18A suggests that Kif18A not only plays a critical (B) Expression of Kif18A protein in breast cancer tissues and their adjacent normal tissues. Normal (N) and tumor (T) samples were extracted with 1% NP-40 lysis buffer and cell lysates were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis followed by immunoblotting analysis using a-Kif18A antibody and anti-b-actin antibody (loading control). (C) Expression of Kif18A protein in breast cancer cell lines. Cells were extracted as in (B) and cell lysates were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis followed by immunoblotting analysis using a-Kif18A antibody and anti-b-actin antibody (loading control).
C.Zhang et al.
role in regulating spindle/chromosome segregation in mitosis (19) but also might have a crucial role in regulating MT array function, such as cell migration during interphase.
To determine if suppression of Kif18A expression perturbs cell growth, we ablated expression of Kif18A in breast cancer cell lines, MDA-MB-231 and MCF7, using mammalian vector-based RNA interference. A pair of oligonucleotides targeting 495-513 bp in the coding region of the Kif18A gene was synthesized and inserted into the pGCsi-U6/Neo/GFP siRNA expression vector. As control, nonsense oligonucleotides were also inserted into the same vector. MDA-MB-231 cells or MCF7 cells were transfected with Kif18A siRNA expression vector or control siRNA expression vector. After G418 selection, stable transfectants were obtained. We selected two Kif18A RNAi MDA-MB-231 clones (Kif18A RNAi-12 and Kif18A RNAi-18), two Kif18A RNAi MCF7 clones (Kif18A RNAi-17 and Kif18A RNAi-20) as well as their control RNAi clones for further analyses. Immunoblotting analysis indicated that expression levels of Kif18A protein were markedly suppressed in Kif18A siRNA transfected cells when compared with those in control siRNA-transfected cells or parental cells ( Figure 4A ). Cell cycle profile examined by fluorescence activated cell sorting analysis indicated more G 2 /M cells in Kif18A RNAi cells compared with control siRNA cells (17.30% ± 0.36 versus 14.27% ± 0.31). Given the fact that Kif18A was stably silenced in these cells, we proposed that these cells may have prolonged G 2 /M phase so that cell proliferation might be inhibited.
Cell proliferation analyses showed that long-term suppression of Kif18A in MDA-MB-231 significantly inhibited cell growth. Kif18A RNAi-12 and Kif18A RNAi-18 cells grew much slower than parental or control cells in MTT assay ( Figure 4B ). Soft agar colony formation assay also revealed that Kif18A RNAi-12 and Kif18A RNAi-18 cells formed smaller and fewer colonies than parental or control cells ( Figure 4C and D) . Similar inhibition of cell proliferation was also observed in HeLa cells transiently transfected with a pool of endonuclease-prepared Kif18A siRNAs (Kif18A esiRNA) [data not shown and (19)]. Thus, these results indicate that long-term or short-term suppression of Kif18A expression in human cancer cells inhibits cells proliferation in vitro.
We next performed xenograft assays in nude mice to determine if long-term suppression of Kif18A in MDA-MB-231 cells was able to affect tumor growth in vivo. Kif18A RNAi, control RNAi or parental cells (1 Â 10 6 ) were injected into fat pads of breasts of female athymic nude mice (n 5 6 per group). Tumor formation and volume of the tumor in each mouse were examined, measured and recorded for seven weeks and tumor growth curves were determined. As shown in Figure  4E , tumor formation and tumor growth of Kif18A RNAi cells were significantly reduced in nude mice when compared with those of control RNAi or parental cells. Seven weeks after inoculation, mice were killed and tumor xenografts were obtained. Consistently, weight measurement showed that tumor xenografts from control or parental cells were much heavier than those from Kif18A RNAi cells ( Figure 4F ). 2) were grown on coverslips and fixed with 4% formaldehyde followed by immunofluorescent staining for a-tubulin (red) and DNA (blue). Representative images were shown. (C) Cells as in (B) were analyzed and counted for multinucleation under an ultraspectral confocal microscopy. More than 300 cells per experiment were analyzed, and the percentages of multinucleated cells were calculated and shown in histograms. Three independent experiments were conducted.
Ã P , 0.01. (19)]. Time-lapse microscopy showed that, in contrast to control cells, cells transfected ) were cultured in six-well soft agar plates and analyzed by soft agar colony formation assay. After three weeks, cells were stained by 0.02% iodonitrotetrazolium chloride, photographed (C) and counted using Image-pro Plus software (D). Three independent experiments were conducted.
Ã P , 0.01. (E and F) 1 Â 10 6 cells as in (A) were inoculated into the mammary fat pad of athymic nude (nu/nu) mice and tumor growth was recorded with a caliper-like instrument. Tumor volumes were calculated according to the formula volume 5 (width 2 Â length)/2 (E). After 7 weeks, all mice were killed and final tumor tissues were isolated and photographed. Representative tumor tissues were shown (F). Two independent experiments were conducted.
with Kif18A esiRNA displayed aberrant spindle rotations as spindle MT bundles (presumably K-fibers) searched, attached and/or tried to align chromosomes at metaphase (supplementary videos S1 and S2 are available at Carcinogenesis Online). These MT bundles were often seen to polymerize and extended themselves crossing-over cell equators into the other half spindles, which were rarely observed in the spindles in control cells. The disorganized spindles and abnormal spindle MT dynamics in Kif18A esiRNA-treated cells greatly perturbed chromosome congression and alignment (shown as the darker backgrounds), resulting in delays of the prometaphase to metaphase and the metaphase to anaphase transitions for several hours [data not shown in video S2 (available at Carcinogenesis Online) and also see supplementary video S8 in Zhu et al. (19) ]. Together, these results indicated that depletion of Kif18A could greatly affect spindle organization and spindle MT dynamics especially kinetochore K-fiber polymerization/depolymerization that are crucial for chromosome segregation and then inhibited cell proliferation.
Second, ablation of Kif18A could also affect the critical nonmitotic function of Kif18A as long-term suppression of Kif18A expression inhibited cell proliferation but not completely blocked cell division. Given the fact that Kif18A is a plus-end-directed MT depolymerase and also localized at cytoplasmic MT array plus-ends in interphase cells, we suspected that suppression of Kif18A expression might perturb MT plus-end dynamics thereby inhibiting cell migration and cell proliferation. To test this possibility, we performed cell migration assay using polycarbonate membrane transwell chambers in MCF-7 cells transfected with Kif18A esiRNA or control Luc esiR-NA. As shown in Figure 5A and B, MCF-7 cells transfected with Kif18A esiRNA displayed much lower (3-to 7-fold) transwell migratory rates than control cells. Similar results were obtained with another siRNA targeting Kif18A (data not shown). Because MT plusend dynamics at leading edges of migrating cells is crucial for cell migration (33), we next examined if suppression of Kif18A expression in cells perturbed MT plus-end dynamics. To this end, we performed time-lapse microscopy in Luc or Kif18A esiRNA-transfected HeLa cells stably expressing a MT plus-end marker, GFP-EB1, to monitor MT plus-end dynamics at leading edges. As shown in Figure 5C and D and supplementary videos S3 and S4 (available at Carcinogenesis Online), the velocity of GFP-EB1 at leading edges of Kif18A esiR-NA-treated cells was 2.65-fold faster than that of Luc esiRNA-treated cells (0.37 ± 0.13 lm/s versus 0.14 ± 0.04 lm/s), indicating that suppression of Kif18A expression results in more dynamic microtubules at leading edges of cells. Together, these results indicate that, by perturbing MT plus-end dynamics, suppression of Kif18A expression not only affects cell division but also cell migration thereby preventing tumorigenesis and tumor development.
Loss of Kif18A promotes anoikis via inactivation of Akt kinase
Finally, we sought to determine the ultimate consequence of longterm loss of Kif18A in human breast cancer cells. Since suppression Kif18A is involved in human breast carcinogenesis of Kif18A expression inhibited anchorage-independent growth of cancer cells, we decided to monitor cell survival of Kif18A RNAi-17 and Kif18A-RNAi-20 as well as control RNAi cells ( Figure 6 ) after detachment and replating in dishes coated with polyhydroxyethylmethacrylate. Cell anoikis assay revealed that, after 18 h of anchorage deprivation on polyhydroxyethylmethacrylate plates, Kif18A RNAi cells displayed significantly increased anoikis as compared with control siRNA-treated or parental cells using Annexin V fluorescein isothiocyanate/propidium iodide staining assay ( Figure 6A ). Thus, these results indicate that long-term loss of Kif18A in MCF7 cells decreases anchorage-independent growth and induces cell anoikis.
To explore the underlying mechanisms by which Kif18A depletion induces anoikis of MCF-7 cells, we examined the potential effects of Kif18A depletion on several known signaling pathways associated with anoikis by immunoblotting analysis (29, 34) . As shown in Figure 6B , suppression of Kif18A expression resulted in downregulation of Akt Ser473 phosphorylation. In contrast, Erk Tyr204 phosphorylation or epidermal growth factor receptor expression was not affected in these cells when compared with control cells. These results indicate that loss of Kif18A disrupts cell survival under anchorage-independent conditions via suppression of the phosphatidylinositol 3-kinase-Akt signaling pathway in MCF-7 cells.
Discussion
We investigated the involvement of the kinesin motor protein, Kif18A, in human breast cancer carcinogenesis. Our results indicate that Kif18A is overexpressed in human breast cancers and such 6 ) were suspended in the polyhydroxyethylmethacrylate-coated wells and cultured in a humidified (37°C, 5% CO 2 ) incubator. After 18 h of growth in suspension, cells were harvested and measured for anoikis using Annexin V-FITC apoptosis detection kit followed by flow cytometry analysis. (B) Cells as in (A) were lysed and cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting analysis using indicated antibodies. b-actin was used as loading control.
overexpression is correlated significantly with tumors in advanced grade, metastasis and poor survival rate, suggesting that Kif18A plays an important role in human breast cancer carcinogenesis, especially tumor progression and/or metastasis. Consistent with these findings, we show that ectopic overexpression of Kif18A in human breast cancer cells results in multinucleation, a characteristic of aneuploidy/polyploidy that is associated with tumor development and progression. Given the fact that Kif18A is a MT plus-end-directed motile depolymerase localized at MT plus-ends of interphase cytoskeleton array and mitotic spindle [(17) and Figure 3A] , our results suggest that overexpression of Kif18A increases Kif18A at MT plus-ends that could perturb cytoskeleton MT array dynamics and/or mitotic spindle formation thereby promoting abnormal cell movement and cell division, ultimately causing cell transformation, tumor progression and metastasis. Recently, overexpression of other MT depolymerase, mitotic centromere-associated kinesin or oncoprotein Op18/stathmin that is involved in controlling interphase cytoskeleton and mitotic spindle MT dynamics, were also reported in several human cancers and upregulation of mitotic centromere-associated kinesin or Op18 expression in cancers was associated with lymphatic invasion, lymph node metastasis and poor prognosis (35, 36) .
We determined the potential role of Kif18A in tumor formation and progression. Our results reveal that suppression of Kif18A expression by RNAi in short or long term in breast tumor cells or HeLa cells inhibit cell proliferation in vitro and/or tumor formation in vivo. The inhibition of cell proliferation and tumorigenesis by Kif18A depletion is due, at least in part, to perturbations of mitotic spindle function and interphase MT array dynamics. Consistent with previous reports (15, 17) , our results reveal that inhibition of Kif18A function greatly affects mitotic spindle function, chromosome segregation and cell division in tumor cells, demonstrating the critical role of Kif18A in mitosis. Furthermore, our results also show that suppression of Kif18A expression in cancer cells perturbs interphase cytoskeleton MT array dynamics, especially MT plus-end dynamics at cell leading edges in non-mitotic cells. Such suppression results in significant reduction of tumor cell migration and anchorage-independent growth. Previous studies demonstrated that regulation of MT dynamics in non-mitotic cells is critical for establishment of the interphasepolarized cytoskeleton MT array and stabilization of MT plus-ends in the array at the leading edges is necessary for cell migration and proliferation (33) . More recently, Kif18A has been demonstrated to inhibit dynamic instability of interphase MTs (27) . Our results are consistent with these findings, indicating that deregulation of Kif18A expression, such as overexpression, in tumor cells not only promotes abnormal chromosome segregation and cell division (aneuploidy/ polyploidy) but also enhances cell migration, movement and anchorage-independent growth.
Ablation of Kif18A function in tumor cells ultimately induces cell anoikis. Anoikis is a specific mode of cell death that results from inadequate or inappropriate cell-matrix interactions and anchorageindependent growth (34) . Although normal cells use anoikis to prevent cell proliferation at inappropriate locations, tumor cells often overcome the process by acquiring the ability to detach from the extracellular matrix and migrate to new sites for their aberrant growth. Thus, enhancement of migration ability and resistance of anoikis provide an advantage for cancer cell metastasis. Since inhibition of Kif18A function in breast cancer cells decreases their anchorage-independent growth and induces anoikis, our results further suggest that perturbation of cytoskeleton MT dynamics by Kif18A overexpression in tumor cells enhances tumor growth, survival and metastasis. Although the exact mechanism by which Kif18A is directly involved in regulating anoikis remains to be determined, our results suggest that the cell proliferation/ survival of phosphatidylinositol 3-kinase-Akt signaling pathway might be activated in Kif18A-dependent, anchorage-independent detached cell growth. Further investigation is required to determine how MT dynamics regulated by Kif18A activates the phosphatidylinositol 3-kinase-Akt signaling pathway.
In summary, our study demonstrates that the kinesin motor protein, Kif18A, plays an important role in human breast cancer carcinogenesis, especially in tumor development, progression and metastasis. As MTs and MT-associated proteins are significant drug targets for cancer chemotherapy (33, (37) (38) (39) , Kif18A might serve as a potential therapeutic drug target for human breast cancer.
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